部份中文踢磷处方资料（仅供参考）
商品名：Kiklin Capsules
英文名：Bixalomer
中文名：踢磷胶囊
生产商：安斯泰来制药
药品简介
近日，Astellas Pharma公司的治疗慢性肾病透析的高磷血症的药物bixalomer已获日本批准。商品名为Kiklin。
bixalomer是胺磷酸盐结合剂，通过降低胃肠道的血清无机磷浓度，从而抑制磷酸盐吸收。此次批准的Kiklin，规格为250mg胶囊剂，每日3次，每次500mg，餐前服用。日最大剂量不超过7500mg。
该药适用于接受透析的慢性肾病患者的高磷血症治疗
キックリンカプセル250mg
药用类别名称
高血症治疗剂(磷酸盐结合聚合物)
批准日期：2012年5月
商標名
Kiklin Capsules 250mg
一般名
ビキサロマー（Bixalomer）
本質
〔日本名〕ビキサロマーは、N,N,N’,N’-テトラキス（3-アミノプロピル）ブタン-1,4-ジアミンと 2-（クロロメチル）オキシランが1：2.1-2.4の比で反応して得られた架橋重合体である。
〔英名〕Bixalomer is a cross-linked polymer which is obtained by a reaction between N,N,N’,N’-tetrakis（3-aminopropyl）butane-1,4-diamine and 2-（chloromethyl）oxirane with a ratio of 1：2.1-2.4.
性状：
它是白色波段淡黄色的粉末。 几乎不溶于水和乙醇 (99.5)。 它是吸湿的。
批准条件
制定药品风险管理计划并加以实施。
药用药理学
1. 药理作用
(1) 血浆磷浓度和Caxp产品降低效果
高磷饲料喂养在慢性肾病大鼠中切除的5/肾, 双色菌由3%的混合饲料给药, 血浆磷浓度 (AUC 值)和Caxp产品(AUC值) 显著降低。此外, 在腺嘌呤诱导的慢性肾病大鼠中, 双碱胺由3% 的混合饲料给药、血浆磷浓度(AUC值)和Caxp产物(AUC 值)显著降低。
(2) 血管钙化的抑制作用
在维生素D负荷腺嘌呤诱导的慢性肾病大鼠中, 双色体由2%的混合饲料给药, 主动脉中的钙含量明显降低。
(3) 继发性甲状旁腺甲状腺功能障碍的改善
高磷饮食喂养慢性肾病大鼠中的高磷饮食、3%的混合饲料给药、血浆PTH浓度(AUC值) 和甲状旁腺重量比显著降低。 此外, 在腺嘌呤引起的慢性肾病大鼠中, 双色体占饲料给药的3%, 血浆PTH浓度(AUC值)和甲状旁腺重量比显著降低。
(4) 肾骨萎缩病进展的抑制作用
在腺嘌呤诱导的慢性肾病大鼠中, 双基体由3% 的饲料给药, 以降低股骨的空隙比和纤维化面积比。在亲切的骨面积比方面, 观察到由于双鱼体给药的原因有显著变化。
(5) 对血液pH值和碳酸氢盐离子浓度的影响
在腺嘌呤诱导的慢性肾病大鼠中, 双色体3%通过饲料给药, 以提高血液pH值和血液碳酸氢盐离子浓度的降低。
2. 作用机制
双色菌是一种氨基功能磷酸盐结合聚合物, 通过促进磷排泄到粪便中并与胃肠道磷酸结合, 减少血液中磷浓度抑制胃肠道对磷的吸收。
适应症
慢性肾病患者高线性血症的改善
用法与用量
成人, 第一剂量500mg作为双色剂, 口服前三次, 每天三次。此后, 症状, 虽然适当增加或减少血清磷浓度的程度, 最大剂量是 1天7500毫克。
包装
100粒(10粒x10)
500粒(10 粒x50)
製造和銷售來源
安斯泰来制药
注：以上中文不够完整，使用者以原处方资料为准。
完整说明附件：http://www.info.pmda.go.jp/go/pack/2190032M1027_1_11/ 

Brand Name:Kiklin
Active Ingredients: Bixalomer
Manufacturer: Astellas
Country of Origin: Japan
Intended Patient: Unisex
Kiklin (Bixalomer) - 250mg (100 Capsules)
Kiklin (Bixalomer) is a medicine used to treat dialysis patients (who have chronic renal failure) for a condition called hyperphosphatemia, in which abnormally high amounts of phosphates occur in the blood. A buildup of phosphorus can affect patients who are receiving kidney dialysis, and it may be caused by an insufficient excretion of phosphorus in the urine. This may lead to renal osteodystrophy, and can even increase the risk of artery calcification and cardiovascular side effects. The goal of treatment with this drug is to reduce the phosphate concentration in the blood by encouraging the excretion of phosphorus in the feces.
Dosage and Administration
Your physician will determine the correct dosage of Kiklin (Bixalomer) that is required based on your individual circumstances. This drug is in capsule form, and the medicine content for each individual capsule is 250mg. Some physicians have instructed their patients to begin treatment with 2 capsules taken 3 times per day. It is normally administered right before the consumption of each main meal of the day. However, the physician providing medical care may decide to adjust the dosage, with factors such as the blood phosphorus level being taken into account. Never exceed the dosage that your physician tells you to take.
Side effects
Some reactions have been reported by patients taking Kiklin (Bixalomer) and a list of examples is given here:
Indigestion
Constipation
Feeling bloated
Abdominal symptoms
Harder than normal feces
Promptly notify your physician if side effects are noticed during the course of treatment. There have been reports of serious reactions in patients treated with this medicine, however, this is a less common occurrence. You will require immediate medical treatment or hospitalization if you notice ischemic enterocolitis symptoms, ulceration, signs of gastrointestinal hemorrhage or any other significant and dangerous side effects which have not been mentioned in this paragraph.
Precautions
You will most likely be directed by your physician to reduce or restrict the amount of phosphorus consumed. Special instructions related to diet may be provided, and it is vital that you strictly adhere to all special dietary requirements .
Monitoring of your bowel movements on a daily basis may be necessary.